Evoke Pharma Reports First Quarter 2018 Results and Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Evoke Pharma Reports First Quarter 2018 Results and Highlights

Evoke Pharma (EVOK) Tops Q1 EPS by 6c

May 14, 2018 6:37 AM EDT

Evoke Pharma (NASDAQ: EVOK) reported Q1 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19).

Dave Gonyer, R.Ph., President and CEO, stated, After successfully completing our comparative exposure pharmacokinetic (PK) trial late last year, we entered 2018 with a discovery of sex-based PK differences for Gimoti. With this significant finding and additional direction from the U.S. Food and Drug Administration (FDA), we are in the process of finalizing our 505(b)(2) New Drug Application (NDA) for Gimoti. The proposed indication for Gimoti is the relief of symptoms of acute and recurrent diabetic gastroparesis in... More